Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Recruiting 4Completed 4Withdrawn 2Terminated 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Lymphoid 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Endometrial Neoplasms 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Antibodies, Monoclonal × Clear all
NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Endometrial Neoplasms

NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05462496 2024-10-15

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06455072 2024-06-12

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Fujian Cancer Hospital

Phase 2 Recruiting
37 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡